Logo preloader

OVERCOME CANCER RESISTANCE

NETRIS Pharma develops first-in-class therapeutics to overcome resistance in oncology by targeting Netrin-1
visuel information

Best-in-Class Environment to foster Therapeutic Innovation

NETRIS Pharma is the first spin-off of Centre Léon Bérard and the Cancer Research Center of Lyon – CRCL – (Lyon, France) and benefits from the exceptional environment of this world’s renowned comprehensive center dedicated to cancer care, education and research.

IMG_0243 recadré4
visuel information

Innovative Therapeutic Approach

By developing therapeutic products targeting a novel mechanism of cancer resistance, we offer patients new solutions alleviating resistance to chemotherapy, targeted therapy and immunotherapy.

IMG_0484 IMG_0382

Our publications

10/18/2024

Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling

08/30/2023

Blockade of netrin-1 is a promising strategy against endometrial cancer - Clinical briefing

08/30/2023

Pharmacological targeting netrin-1 inhibits EMT in cancer

Generated with Avocode.Picto-ampoule-cadenasRectanglePicto-ampoule-cadenasShapeShapePath
Strategic Focus on Intellectual Property Rights

As the world pioneer and leader biopharmaceutical company targeting netrin-1 and ligands of Dependence Receptors, NETRIS Pharma is building a unique portfolio of worldwide exclusive rights and patents on all key elements of its approach.

Our partners

NETRIS Pharma has grown from inception with the full support of Research, Clinical and Corporate Partners.

Clinical
Corporate
Research
Logo-centre-leon-bernard
Logo-HCL
Logo-CHU-Grenoble-Alpes
Logo-Arcagy_gineco
Logo-bpi-france
Logo-région-Auvergne-Rhône-Alpes
Logo-Lyon-Biopole-AURA
Logo-union-européenne
eurekaEurostars
Logo-CLARA
Logo-Inserm
Logo-Université-Lyon-1
anr-logo
Logo-CNRS
Logo-Université-Lyon
CRCL